Toxicities associated with immune checkpoint inhibitors - UpToDate

{{configCtrl2.metaDescription()}}

Overview of toxicities associated with immune checkpoint inhibitors INTRODUCTION Immune checkpoint inhibitors (ICIs), also known as checkpoint inhibitor immunotherapy, are immunomodulatory antibodies that are used to enhance the immune system. These agents have substantially improved the prognosis for patients with many advanced malignancies. The primary targets for checkpoint inhibition include (table 1): ●Programmed cell death receptor 1 and programmed cell death ligand 1 – Multiple antibodies against programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1)…

related reading

• Immunotherapy for Cancer - NCIcancer.gov
• Neoadjuvant immune checkpoint blockade in high-risk resectable melanomanature.com
• Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapyuptodate.com
• Cancer Study Links COVID Shots to Longer Survivalmedpagetoday.com
• Principles of cancer immunotherapy - UpToDateuptodate.com
• Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
• Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
• Cancer cells educate natural killer cells to a metastasis-promoting cell state - PubMedpubmed.ncbi.nlm.nih.gov
• The novel mechanism of lenalidomide activity - PMCncbi.nlm.nih.gov
• Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
• Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexatencbi.nlm.nih.gov
• Thymosin alpha 1: A comprehensive review of the literaturencbi.nlm.nih.gov